Clinical Trials Browser

Phase 3 × Metastatic Castration-Resistant Prostate Cancer × 90 days × Clear all

NCT06629779 2026-06-05

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Phase 3 Recruiting

Metastatic Castration-Resistant Prostate Cancer